Which neurology treatments commonly require prior authorization?
Prior authorization is commonly required for: MS disease-modifying therapies (all high-efficacy agents and many platform therapies); CGRP monoclonal antibodies for chronic migraine; biologics and complement inhibitors for myasthenia gravis; anti-seizure medications when a non-generic or non-formulary agent is prescribed; botulinum toxin for spasticity, cervical dystonia, and chronic migraine; advanced neuroimaging beyond routine MRI; and electrodiagnostic testing in some payer contracts.
The prior authorization landscape changes frequently as payers update formularies, step therapy requirements, and coverage policies. Neurology practices must maintain current knowledge of payer-specific requirements for each treatment they commonly prescribe.
Advanced procedures — deep brain stimulation evaluation and implantation, vagal nerve stimulation, focused ultrasound — require particularly thorough prior authorization documentation establishing diagnosis, disease severity, treatment failure history, and the specific indications for the procedure.
What documentation do neurology prior authorizations require?
Prior authorization packages for neurology treatments typically require: the clinical diagnosis with supporting diagnostic criteria; disease severity documentation (EDSS for MS, headache frequency for migraine, seizure frequency for epilepsy, UPDRS for Parkinson's); prior treatment history with specific agents, doses, treatment duration, and reasons for discontinuation; clinical response to current treatment with objective measures; and a clinical narrative explaining why the requested treatment is medically necessary.
The quality of this documentation is directly predictive of authorization outcomes. A well-documented case with specific, objective measures of disease severity and treatment failure has a substantially higher approval rate than a vague narrative without supporting clinical data.
The documentation required for prior authorization is the same documentation that good clinical care produces — it is not a separate administrative task. When longitudinal clinical records are complete, the prior authorization package is a summary of existing documentation.
How can neurology practices reduce the prior authorization burden?
The most effective approach to reducing prior authorization burden is upstream documentation quality. When every MS visit captures EDSS, relapse history, and current therapy response; when every migraine visit records headache frequency and preventive therapy history; when every epilepsy visit logs seizure frequency and medication levels — the prior authorization package writes itself from existing records.
Practices that approach prior authorization as a documentation event — scrambling to assemble supporting information when authorization is needed — face the highest burden. Practices with systematic, structured longitudinal documentation treat prior authorization as a clerical task rather than a clinical emergency.
Scryber's Transcryber captures these structured elements at every visit, so the documentation investment happens at the point of care and the prior authorization benefit is realized months later when the therapy is requested.
See It in Practice
See how Scryber works for your practice
Transcryber captures every encounter. Visualyzer shows you what you earned, what you collected, and where the gap is.